Leading Russian drugmakers suspend production of cheap drugs

24 December 2014

Some 16 leading Russian pharmaceutical companies have officially announced suspension of the production of cheap drugs, Sergey Kalashnikov, chairman of the Health Committee of the Russian State Duma (Parliament), has said.

According to Mr Kalashnikov, this is mainly due to the increase of prices for imported substances, caused by the economic crisis in Russia and devaluation of national currency – the rouble, reports The Pharma Letter’s local correspondent.

Among the drugs for which production has been suspended are some essential medicines that are regularly delivered to hospitals of Russia. In the meantime, the Russian government is currently designing ways, which should prevent a potential shortage of drugs in the local market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >